|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125045 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-20 16:37:41 |
|
注册时间: Date of Registration: |
2026-05-20 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
甲氧西林耐药葡萄球菌治疗用药的临床综合评价 |
|
Public title: |
Clinical Comprehensive Evaluation of Drugs for the Treatment of Methicillin-Resistant Staphylococci |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
甲氧西林耐药葡萄球菌治疗用药的临床综合评价 |
|
Scientific title: |
Clinical Comprehensive Evaluation of Drugs for the Treatment of Methicillin-Resistant Staphylococci |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
高萍 |
研究负责人: |
张雅慧 |
|
Applicant: |
Gao Ping |
Study leader: |
Zhang Yahui |
|
申请注册联系人电话: Applicant telephone: |
+86 531 6877 6461 |
研究负责人电话:
Study leader's |
+86 531 6877 6461 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
gaoping_candice@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangyy1982@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市经五路324号 |
研究负责人通讯地址: |
山东省济南市经五路324号 |
|
Applicant address: |
No. 324, Jingwu Road, Jinan City, Shandong Province |
Study leader's address: |
No. 324, Jingwu Road, Jinan City, Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东省立医院 |
||
|
Applicant's institution: |
Shandong Provincial Hospital |
||
|
研究负责人所在单位: |
山东省立医院 |
||
|
Affiliation of the Leader: |
Shandong Provincial Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
省医伦批第(SWYX:NO.2024-1057) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东省立医院涉及人的生物医学研究伦理委员会 |
||
|
Name of the ethic committee: |
Biomedical Research Ethics Committee Involving Humans, Shandong Provincial Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-26 00:00:00 | ||
|
伦理委员会联系人: |
杨爱辉 |
||
|
Contact Name of the ethic committee: |
Aihui Yang |
||
|
伦理委员会联系地址: |
山东省济南市经五路324号 |
||
|
Contact Address of the ethic committee: |
No. 324, Jingwu Road, Jinan City, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 6877 6025 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东省立医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shandong Provincial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市经五路324号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 324, Jingwu Road, Jinan City, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
No funding |
||||||||||||||||||||||
|
研究疾病: |
感染 |
||||||||||||||||||||||
|
Target disease: |
infection |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
通过真实世界研究比较常用甲氧西林耐药葡萄球菌治疗用药((去甲)万古霉素或替考拉宁或利奈唑胺或达托霉素)的安全性和有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the safety and efficacy of commonly used drugs (vancomycin or teicoplanin or linezolid or daptomycin) for the treatment of methicillin-resistant staphylococci (MRSA) in a real-world study. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.确诊或疑似革兰阳性菌(如葡萄球菌、链球菌、肠球菌、棒状杆菌等)感染的住院患者,可以包括各种类型感染,如血流感染、感染性心内膜炎、呼吸系统感染、腹腔感染、皮肤软组织感染、骨关节感染、中枢神经系统感染和泌尿道感染; 2. 使用研究药物:(去甲)万古霉素或替考拉宁或利奈唑胺或达托霉素; 3.年龄不限; 4.性别不限; 5.种族不限。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Hospitalized patients with confirmed or suspected Gram-positive bacterial infection (such as staphylococcus, streptococcus, Enterococcus, corynebacterium, etc.) can include various types of infection, such as bloodstream infection, infective endocarditis, respiratory system infection, abdominal infection, skin and soft tissue infection, bone and joint infection, central nervous system infection, and urinary tract infection. 2. Use of study drugs: (norepinephrine) vancomycin or teicoplanin or linezolid or daptomycin; 3. No age limit; 4. Gender is not limited; 5. No race limit. |
||||||||||||||||||||||
|
排除标准: |
1.使用初始目标药物时长低于三天; 2.无法获得治疗前后足够数据用于疗效评价; 3.患者本次感染时曾在外院使用目标药物; 4.非标准给药途径给药,如万古霉素用于冲洗等; 5.同时联合其他本研究药物; 6.患者或家属拒绝签署知情同意书参与该研究; 7.使用目标药物前曾使用其他研究药物。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Use of the initial target drug for less than three days; 2. Insufficient data before and after treatment were available for efficacy evaluation.; 3. The patient had used the target drug in another hospital at the time of this infection. 4. Non-standard route of administration, such as vancomycin for irrigation; 5. Other drugs of this study were combined at the same time. 6. Patients or their families refused to sign informed consent to participate in the study. 7. Use of other study drugs was preceded by use of the target drug. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-01 00:00:00至 To 2026-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-01-02 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究公开发表后半年,邮件联系研究负责人合理获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the publication of the research, contact the research leader via email to obtain reasonable information. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |